<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000959" GROUP_ID="MUSKEL" ID="710299082413025590" MERGED_FROM="" MODIFIED="2010-05-25 15:27:53 -0400" MODIFIED_BY="Michelle Foote" REVIEW_NO="C005-R" REVMAN_SUB_VERSION="5.0.24" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2010-05-25 15:27:53 -0400" MODIFIED_BY="Michelle Foote">
<TITLE>Antimalarials for treating rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-05-25 15:27:53 -0400" MODIFIED_BY="Michelle Foote">
<PERSON ID="15002" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Maria</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Suarez-Almazor</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>msalmazor@mdanderson.org</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>General Internal Medicine, Ambulatory Treatment and Emergency Care</DEPARTMENT>
<ORGANISATION>The University of Texas, M.D. Anderson Cancer Center</ORGANISATION>
<ADDRESS_1>1515 Holcombe Blvd</ADDRESS_1>
<ADDRESS_2>Unit 1465</ADDRESS_2>
<CITY>Houston</CITY>
<ZIP>77030</ZIP>
<REGION>Texas</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 713 745 4516</PHONE_1>
<PHONE_2/>
<FAX_1>1 713 563 4491</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="9254" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Elaine</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Belseck</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>ebelseck@cha.ab.ca</EMAIL_1>
<EMAIL_2>ebelseck@cha.ab.ca</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Pediatrics</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>2C3.67 Walter C Mackenzie</ADDRESS_1>
<ADDRESS_2/>
<CITY>Alberta</CITY>
<ZIP>T6G 2R7</ZIP>
<REGION/>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 492 1078</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 8538</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5440" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Beverley</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Shea</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>bevshea@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Population Health</DEPARTMENT>
<ORGANISATION>University of Ottawa</ORGANISATION>
<ADDRESS_1>1 Stewart St.</ADDRESS_1>
<ADDRESS_2>Room 312</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 562 5800 ext: 8571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5318" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Homik</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Clinical Professor of Medicine</POSITION>
<EMAIL_1>joanne.homik@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Deparment of Medicine</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>562 Heritage Medical Research Centre</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2S2</ZIP>
<REGION>Alberta</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 780 407 8070</PHONE_1>
<PHONE_2/>
<FAX_1>+1 780 407 6055</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12662" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>George</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Wells</LAST_NAME>
<SUFFIX>PhD, MSc</SUFFIX>
<POSITION>Director</POSITION>
<EMAIL_1>gawells@ottawaheart.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cardiovascular Research Reference Centre</DEPARTMENT>
<ORGANISATION>University of Ottawa Heart Institute</ORGANISATION>
<ADDRESS_1>Room H1-1</ADDRESS_1>
<ADDRESS_2>40 Ruskin Street</ADDRESS_2>
<CITY>Ottawa</CITY>
<ZIP>K1Y 4W7</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+1 613 798 5555 x18640</PHONE_1>
<PHONE_2>+1 613 798 5555 x18642</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5474" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Tugwell</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>elacasse@uottawa.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Centre for Global Health, Institute of Population Health, Department of Medicine</DEPARTMENT>
<ORGANISATION>Ottawa Hospital</ORGANISATION>
<ADDRESS_1>1 Stewart Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ottawa</CITY>
<ZIP>K1N 6N5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>613-562-5800 ext: 1945</PHONE_1>
<PHONE_2/>
<FAX_1>613-562-5659</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-09-22 00:34:01 -0400" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="8" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="8" YEAR="2002"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2008-09-22 00:33:49 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-22 00:33:49 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format. C005-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-22 00:34:10 -0400" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Alberta Hospitals Foundation</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-09-22 00:49:56 -0400" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-09-22 00:49:56 -0400" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-09-22 00:37:44 -0400" MODIFIED_BY="[Empty name]">Antimalarials for treating rheumatoid arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2008-09-22 00:49:56 -0400" MODIFIED_BY="[Empty name]">
<P>Antimalarials have been used for the treatment of rheumatoid arthritis (RA) for several decades. This review found four trials, with 300 patients receiving hydrochloroquine and 292 receiving placebo. A benefit was observed in the patients taking hydroxychloroquine compared to placebo. There was no difference between the two groups in terms of those who had to withdraw from trials due to side effects. </P>
<P>Hydroxychloroquine appears to be helpful for the treatment of RA. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Antimalarials have been used for the treatment of rheumatoid arthritis (RA) for several decades. Recently several trials have been published with larger sample sizes, and better design than previous studies. These newer trials have evaluated the efficacy and toxicity of hydroxychloroquine.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the short-term efficacy and toxicity of antimalarials for the treatment of rheumatoid arthritis (RA).</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register, MEDLINE and EMBASE up to and including August 2000. We also carried out a handsearch of the reference lists of the trials retrieved from the electronic search.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing antimalarials against placebo in patients with RA</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data abstraction was carried out independently by two reviewers. The same two reviewers using a validated checklist (Jadad 1996) assessed the methodological quality of the RCTs and CCTs. Rheumatoid arthritis outcome measures were extracted from the publications for the 6-month endpoint. The pooled analysis was performed using standardized mean differences for joint counts, pain and global assessments. Weighted mean differences were used for erythrocyte sedimentation rate (ESR). Toxicity was evaluated with pooled odds ratios for withdrawals. A chi-square test was used to assess heterogeneity among trials. Fixed effects models were used throughout.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We found four trials, with 300 patients randomized to hydrochloroquine and 292 to placebo. Only trials evaluating hydroxychloroquine could be pooled in the analysis. A statistically significant benefit was observed when hydroxychloroquine was compared to placebo. The standardized mean differences for the various outcome measures ranged from -0.33 to -0.52, and were statistically significant. Statistically significant differences were also observed for ESR. Overall withdrawals and withdrawals due to lack of efficacy were significantly more frequent in the placebo group. No differences were observed in withdrawals due to toxicity.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Hydroxychloroquine appears to be efficacious for the treatment of RA. Its overall effect appears to be moderate, but its low toxicity profile should be considered when treating patients with RA.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Antimalarials have been used for the treatment of rheumatoid arthritis (RA) for several decades. Although several clinical trials were published in the past, these often had small sample sizes and showed wide discrepancies in their results and sometimes used higher dosages than those accepted today (see table of excluded studies). Several clinical trials have been published this decade with larger sample sizes, and better design. These newer trials have evaluated the efficacy and toxicity of hydroxychloroquine.</P>
</BACKGROUND>
<OBJECTIVES>
<P>To evaluate the short-term efficacy and toxicity of antimalarials for the treatment of RA, by conducting a systematic review of randomized controlled trials (RCTs) and controlled clinical trials (CCTs) comparing hydroxychloroquine with placebo.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>Randomized controlled trials (RCTs) and controlled clinical trials (CCTs), with a minimum duration of the study of 6 months.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with a diagnosis of RA (as stated in the publication)</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Intervention group:<BR/>a) Chloroquine &gt;= 250 mg/day or<BR/>b) Hydroxychloroquine &gt;= 400 mg/day</P>
<P>Control group: placebo</P>
<P>Duration of treatment in double-blind phase &gt;= 6 months</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>EFFICACY:<BR/>All the outcome measures in OMERACT (<LINK REF="REF-OMERACT-1993" TYPE="REFERENCE">OMERACT 1993</LINK>) were included for potential analysis, although only some were consistently measured.</P>
<P>OMERACT measures for efficacy include:<BR/>a) Number of tender joints per patient<BR/>b) Number of swollen joints per patient<BR/>c) Pain<BR/>d) Physician global assessment<BR/>e) Patient global assessment<BR/>f) Functional status<BR/>g) Acute phase reactants<BR/>h) Radiological damage</P>
<P>Additionally, the following measures were recorded if included in the publication:<BR/>a) Number of patients fulfilling response criteria (American College of Rheumatology, Paulus)<BR/>b) Number of patients in remission at the end of the trial<BR/>c) Total number of withdrawals and dropouts<BR/>d) Number of withdrawals from lack of efficacy</P>
<P>TOXICITY<BR/>Toxicity was evaluated with the number of withdrawals and dropouts including:<BR/>a) Number of withdrawals due to adverse reactions<BR/>b) Number of withdrawals due to system-specific adverse reactions (e.g. gastrointestinal, renal, etc.)</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>1. Electronic searches<BR/>We searched MEDLINE using the strategy developed by <LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK> up to and including August 2000,<BR/>EMBASE was searched from 1988 to August 2000, with a strategy similar to the one used for MEDLINE, the Cochrane Musculoskeletal Group's trials register, the Cochrane Controlled Trials Register issue 3, 2000.</P>
<P>2. Hand searches<BR/>Reference lists of all the trials selected through the electronic search were manually searched to identify additional trials. </P>
<P>3. The Cochrane Controlled Trials Register (CCTR) was also searched.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Data extracted from the publications included study characteristics and outcome measures of efficacy and toxicity.</P>
<P>1. Efficacy</P>
<P>The results on efficacy were analysed for the 6 month endpoints. Although some trials had longer duration, this endpoint was chosen because it was reported in most trials. </P>
<P>The standard deviations were not reported in one trial (<LINK REF="STD-Clark-1993" TYPE="STUDY">Clark 1993</LINK>), and we estimated them using the coefficient of variation calculated from the other trials, and weighted by sample size. An additional study reported medians and interquartile ranges. Medians were entered as means, and the interquartile ranges were divided by two to estimate the standard deviation. </P>
<P>End-of-trial results were pooled as standardized mean differences (SMDs) for joint scores, pain, global, and functional assessments. This was necessary because of the variation in the outcome measures included in each study (e.g. different number of swollen joints). Trial results were entered in RevMan 3.0 using the same direction to enable the pooling of results with the lower values indicating a better response. Negative values in standardized weighted means indicate a benefit of the active drug over placebo. ESR results were pooled using weighted mean differences.</P>
<P>2. Withdrawals and dropouts</P>
<P>Withdrawals and dropouts at the end of the study were pooled for all trials. Pooled odds ratios (OR) were estimated using Peto's method (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). Toxicity was analysed for total withdrawals from adverse reactions, and withdrawals for system specific side effects.</P>
<P>The heterogeneity of the trials for each pooled analysis was estimated using a chi-square test.</P>
<P>Fixed effects models were used throughout.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Four RCTs and CCTs (<LINK REF="STD-Blackburn-1995" TYPE="STUDY">Blackburn 1995</LINK>, <LINK REF="STD-Clark-1993" TYPE="STUDY">Clark 1993</LINK>, <LINK REF="STD-Davis-1991" TYPE="STUDY">Davis 1991</LINK>, <LINK REF="STD-HERA-1995" TYPE="STUDY">HERA 1995</LINK>) met the criteria for inclusion, and reported data suitable for pooling. The patients in these trials were similar as assessed by patient's age, inclusion criteria, duration of disease and activity at entry. In general, patients had relatively early and mild RA, with no prior treatment with DMARDs, and low prevalence of rheumatoid factor (RF). All of the studies evaluated hydroxychloroquine, at 400 mg/day.</P>
<P>Three of the studies reported that the patients had undergone ophthalmologic evaluation, and could be used for the analysis of ocular toxicity.</P>
<P>Eight additional studies had to be excluded because of short duration or inadequate data reported. Some of these studies had evaluated chloroquine (<LINK REF="STD-Cohen-1958" TYPE="STUDY">Cohen 1958</LINK>, <LINK REF="STD-Freedman-1960" TYPE="STUDY">Freedman 1960</LINK>, <LINK REF="STD-Popert-1961" TYPE="STUDY">Popert 1961</LINK>, <LINK REF="STD-Scull-1962" TYPE="STUDY">Scull 1962</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The methodological quality of the studies was assessed using a quality scale validated and published by <LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>. This scale includes an assessment of randomization, double-blinding procedures and description of withdrawals. The possible range of scores is 0 (worst) to 5 (best). Two studies had a score of 5, and the other two a score of 4 (see included tables for details)</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Four trials evaluating hydroxychloroquine against placebo were included in the pooled analysis. In total, 290 patients receiving hydroxychloroquine and 281 receiving placebo were evaluated for efficacy. In the pooled analysis of clinical benefits most efficacy measures considered for the study reached levels of statistical significance of &lt;0.05, favouring hydroxychloroquine over placebo. The standardized mean differences (SMDs) for the various outcome measures were as follows: a) tender joints: -0.33 (95% CI, -0.50,-0.17); b) swollen joints: -0.52 (95% CI, -0.69, -0.36); c) pain: -0.45 (95% CI, -0.63, -0.27); d) physician global assessment; -0.45 (95% CI, -0.66,-0.24); e) patient global assessment: -0.39 (95% CI, -0.59,-0.18). A weighted mean difference (WMD) of 6 mm (95% CI, -8.51, -4.24) favouring hydroxychloroquine was observed for ESR. Only one study measured functional status: no significant differences were observed between hydroxychloroquine and placebo in Health Assessment Questionnaire (HAQ) scores (<LINK REF="STD-HERA-1995" TYPE="STUDY">HERA 1995</LINK>). Another study reported radiological progression (<LINK REF="STD-Davis-1991" TYPE="STUDY">Davis 1991</LINK>); no significant differences were observed between groups.</P>
<P>Tests of homogeneity did not show any one study to be statistically different from the others.</P>
<P>The pooled analysis of withdrawals and dropouts included 299 patients receiving hydroxychloroquine and 292 receiving placebo. Patients receiving hydroxychloroquine were less likely to discontinue treatment, overall (OR = 0.59, 95% CI; 0.41, 0.86), or because of insufficient response (OR = 0.55, 95% CI; 0.33, 0.91). Withdrawals due to adverse reactions were rare (4.7% in the antimalarial group and 5.5% in the placebo group). None of the 3 studies which conducted ophthalmologic evaluations reported withdrawals due to ocular toxicity (<LINK REF="STD-Blackburn-1995" TYPE="STUDY">Blackburn 1995</LINK>, <LINK REF="STD-Clark-1993" TYPE="STUDY">Clark 1993</LINK>, <LINK REF="STD-HERA-1995" TYPE="STUDY">HERA 1995</LINK>). A single patient in the <LINK REF="STD-HERA-1995" TYPE="STUDY">HERA 1995</LINK> trial had mild toxicity, not requiring discontinuation.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>The purpose of this systematic review was to evaluate the efficacy and toxicity of antimalarials for the treatment of patients with RA. Unfortunately, data could only be pooled for trials including hydroxychloroquine, and therefore, our results are limited to this drug. We could not adequately assess the efficacy of chloroquine. Controlled trials including this drug were conducted several decades ago and did not follow standard procedures for reporting the data, such as those proposed by CONSORT (<LINK REF="REF-Begg-1996" TYPE="REFERENCE">Begg 1996</LINK>). </P>
<P>We encountered some difficulties in the data extraction of the included trials. One trial reported medians and another did not include standard deviations. We estimated missing data with approximate values derived from the trial per se (e.g. interquartile range as a measure of dispersion), or from results from the other trials (e.g. coefficient of variation to estimate standard deviations relative to the mean). Although these procedures may have created some bias, because they were similarly applied to both groups (treatment and control), their overall impact on the estimation of differences between groups is probably small. Our preference was to estimate some of these parameters as opposed to completely excluding some trials.</P>
<P>Hydroxychloroquine showed a statistically significant difference when compared with placebo for most of the outcome measures included in the trials. The standardized weighted differences for the various outcomes ranged from -0.33 to -0.52, which can be considered as a modest effect (<LINK REF="REF-Kazis-1989" TYPE="REFERENCE">Kazis 1989</LINK>). A small difference favouring the treatment group was also observed for ESR (6 mm). Total withdrawals and dropouts and withdrawals due to lack of efficacy were also increased in the placebo group, supporting the beneficial effect of hydroxychloroquine. Only one trial examined functional status (Esdaile 1995) and another radiological progression (<LINK REF="STD-Davis-1991" TYPE="STUDY">Davis 1991</LINK>). No significant differences were observed between placebo and hydroxychloroquine for these outcome measures.</P>
<P>Hydroxychloroquine appeared to be very safe in the short-term with no significant adverse effects, other than one case with involvement of the central nervous system. Withdrawals from ocular toxicity were not reported.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Hydroxychloroquine appears to be efficacious for the treatment of RA. Its overall effect appears to be moderate, but its low toxicity profile should be considered when treating patients with RA.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>The use of antimalarials in combination with other therapies is gaining acceptance. Current and future research in this area will determine if the potential of antimalarials can be enhanced through combination with other drugs.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Ms. Brenda Topliss for her assistance in editing this manuscript and the Cochrane Musculoskeletal Group editorial team for their comments.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS/>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Blackburn-1995" NAME="Blackburn 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Blackburn WD, Jr., Prupas HM, Silverfield JC, Poiley JE, Caldwell JR, Collins RL, Miller MJ, Sikes DH, Kaplan H, Fleischmann R, et al. Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxic am alone. Arthritis Rheum. 1995;38:1447-56.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn WD, Jr, Prupas HM, Silverfield JC, Poiley JE, Caldwell JR, Collins RL, Miller MJ, Sikes DH, Kaplan H, Fleischmann R</AU>
<TI>Tenidap in rheumatoid arthritis. A 24-week double-blind comparison with hydroxychloroquine-plus-piroxicam, and piroxic am alone</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>10</NO>
<PG>1447-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1993" NAME="Clark 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark P, Casas E, Tugwell P, Medina C, Gheno C, Tenorio G, Orozco JA</AU>
<TI>Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial [see comments]</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>1067-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-1991" NAME="Davis 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis MJ, Dawes PT, Fowler PD, Clarke S, Fisher J, Shadforth MF</AU>
<TI>Should disease-modifying agents be used in mild rheumatoid arthritis?</TI>
<SO>Br J Rheumatol</SO>
<YR>1991</YR>
<VL>30</VL>
<PG>451-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HERA-1995" NAME="HERA 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Esdaile JM, Suissa S, Shiroky JB, Lamping D, Tsakonas E, Anderson D, Jamali F, Liang MH, Carette S, Cividino A, et al. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am.J.Med. 1995;98: 156-68.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esdaile JM, Suissa S, Shiroky JB, Lamping D, Tsakonas E, Anderson D, Jamali F, Liang MH, Carette S, Cividino A, et al</AU>
<TI>A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study. Am.J.Med</TI>
<YR>1995</YR>
<VL>98</VL>
<PG>156-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-1958" NAME="Cohen 1958" YEAR="1958">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen AS, Calkins E</AU>
<TI>A controlled study of chloroquine as an antirheumatic agent</TI>
<SO>Arthritis Rheum</SO>
<YR>1958</YR>
<VL>1</VL>
<PG>297-312</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Freedman-1960" NAME="Freedman 1960" YEAR="1960">
<REFERENCE NOTES="&lt;p&gt;Freedman A, Steinberg VL. Chloroquine in rheumatoid arthritis. A double blindfold trial of treatment for one year. Ann Rheum Dis 1960;19:243-50&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freedman A, Steinberg VL</AU>
<TI>Chloroquine in rheumatoid arthritis. A double blindfold trial of treatment for one year</TI>
<SO>Ann Rheum Dis</SO>
<YR>1960</YR>
<VL>19</VL>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Freedman A</AU>
<TI>Chloroquine and rheumatoid arthritis. A short-term controlled trial</TI>
<SO>Ann Rheum Dis</SO>
<YR>1956</YR>
<VL>15</VL>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hamilton-1962" NAME="Hamilton 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton EBD, Scott JT</AU>
<TI>Hydroxychloroquine sulfate ('Plaquenil') in treatment of rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1962</YR>
<VL>5</VL>
<PG>502-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kersley-1959" NAME="Kersley 1959" YEAR="1959">
<REFERENCE NOTES="&lt;p&gt;Kersley GD, Palin AG. Amodiaquine and hydroxychloroquine in rheumatoid arthritis. Lancet 1959;2: 885-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kersley GD, Palin AG</AU>
<TI>Amodiaquine and hydroxychloroquine in rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1959</YR>
<VL>2</VL>
<PG>885-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mainland-1962" NAME="Mainland 1962" YEAR="1962">
<REFERENCE NOTES="&lt;p&gt;Mainland D, Sutcliffe M. Hydroxychloroquine sulfate in rheumatoid arthritis, a six month double-blind trial. Bull Rheum Dis 1962;13:287-90&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mainland D, Sutcliffe M</AU>
<TI>Hydroxychloroquine sulfate in rheumatoid arthritis, a six month double-blind trial</TI>
<SO>Bull Rheum Dis</SO>
<YR>1962</YR>
<VL>13</VL>
<PG>287-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Popert-1961" NAME="Popert 1961" YEAR="1961">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Popert AJ, Meijers KAE, Sharp J, Bier F</AU>
<TI>Chloroquine diphosphate in rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1961</YR>
<VL>20</VL>
<PG>18-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinehart-1957" NAME="Rinehart 1957" YEAR="1957">
<REFERENCE NOTES="&lt;p&gt;Rinehart RE, Rosenbaum EE, Hopkins CE. Northwest Medicine 1957;56:703-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinehart RE, Rosenbaum EE, Hopkins CE</AU>
<SO>Northwest Medicine</SO>
<YR>1957</YR>
<VL>56</VL>
<PG>703-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scull-1962" NAME="Scull 1962" YEAR="1962">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scull E</AU>
<TI>Chloroquine and hydroxychloroquine therapy in rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1962</YR>
<VL>5</VL>
<PG>30-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Begg-1996" NAME="Begg 1996" TYPE="JOURNAL_ARTICLE">
<AU>Begg C, Cho M, Eastwood S et al</AU>
<TI>Improving the quality of randomized controlled trials: the CONSORT statement</TI>
<SO>JAMA</SO>
<YR>1996</YR>
<VL>276</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin K., Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K</AU>
<TI>, Scherer R., Lefebvre C. Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1993" NAME="Felson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials</TI>
<SO>Arthritis Rheum</SO>
<YR>1993</YR>
<VL>36</VL>
<PG>729-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M et al</AU>
<TI>American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad A, Moore A, Carrol D, et al</AU>
<TI>Assessing the quality of reports of randomized trials: is blinding necessary?</TI>
<SO>Control Clin Trial</SO>
<YR>1996</YR>
<VL>17</VL>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kazis-1989" NAME="Kazis 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kazis LEE, Anderson JJ, Meenan RF</AU>
<TI>Effect sizes for interpreting changes in health status</TI>
<SO>Medical Care</SO>
<YR>1989</YR>
<VL>27</VL>
<NO>S3</NO>
<PG>S178-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-OMERACT-1993" NAME="OMERACT 1993" TYPE="JOURNAL_ARTICLE">
<AU>OMERACT</AU>
<TI>Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials</TI>
<SO>J Rheumatol</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>526-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" NAME="Petitti 1994" NOTES="&lt;p&gt;Petitti D. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. Oxford University Press, New York 1994:90-114.&lt;br&gt;&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Petitti D</AU>
<TI>Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine</TI>
<PG>90-114</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES>
<REFERENCE ID="REF-Bird-1984" NAME="Bird 1984" NOTES="&lt;p&gt;Bird HA, Le Gallez P, Dixon JS, Surrall KE, Cole DS, Goldman MH, Wright V. A single-blind comparative study of auranofin and hydroxychloroquine in patients with rheumatoid arthritis. Clin Rheumatol 1984;3:Suppl 1:57-66&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Bird HA, Le Gallez P, Dixon JS, Surrall KE, Cole DS, Goldman MH, Wright V</AU>
<TI>A single-blind comparative study of auranofin and hydroxychloroquine in patients with rheumatoid arthritis</TI>
<SO>Clin Rheumatol</SO>
<YR>1984</YR>
<VL>3:Suppl 1</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bunch-1984" NAME="Bunch 1984" TYPE="JOURNAL_ARTICLE">
<AU>Bunch TW, O'Duffy JD, Tompkins RB, O'Fallon WM</AU>
<TI>Controlled trial of hydroxychloroquine and D-penicillamine singly and in combination in the treatment of rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1984</YR>
<VL>27</VL>
<NO>3</NO>
<PG>267-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dwosh-1977" NAME="Dwosh 1977" TYPE="JOURNAL_ARTICLE">
<AU>Dwosh IL, Stein HB, Urowitz MB, Smythe HA, Hunter T, Ogryzlo MA</AU>
<TI>Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine</TI>
<SO>Arthritis Rheum</SO>
<YR>1977</YR>
<VL>20</VL>
<NO>2</NO>
<PG>685-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Faarvang-1993" NAME="Faarvang 1993" TYPE="JOURNAL_ARTICLE">
<AU>Faarvang KL, Egsmose C, Kryger P, Podenphant J, Ingeman-Nielsen M, Hansen TM</AU>
<TI>Hydroxychloroquine and sulphasalazine alone and in combination in rheumatoid arthritis: a randomised double blind trial</TI>
<SO>Ann Rheum Dis</SO>
<YR>1993</YR>
<VL>52</VL>
<NO>10</NO>
<PG>711-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ferraz-1994" NAME="Ferraz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Ferraz MB, Pinheiro GR, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, Brandao L, Silva SC, Pinheiro GC, Atra E</AU>
<TI>Combination therapy with methotrexate and chloroquine in rheumatoid arthritis. A multicenter randomized placebo-controlled trial</TI>
<SO>Sca nd J Rheumatol</SO>
<YR>1994</YR>
<VL>23</VL>
<NO>5</NO>
<PG>231-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fowler-1984" NAME="Fowler 1984" TYPE="JOURNAL_ARTICLE">
<AU>Fowler PD, Shadforth MF, Crook PR, Lawton A</AU>
<TI>Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study</TI>
<SO>Ann Rheum Dis</SO>
<YR>1984</YR>
<VL>43</VL>
<NO>2</NO>
<PG>200-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freedman-1956" NAME="Freedman 1956" TYPE="JOURNAL_ARTICLE">
<AU>Freedman A</AU>
<TI>Chloroquine and rheumatoid arthritis. A short-term controlled trial</TI>
<SO>Ann Rheum Dis</SO>
<YR>1956</YR>
<VL>15</VL>
<PG>251-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallo-1986" NAME="Gallo 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gallo M, La Montagna G, Valentini G</AU>
<TI>[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis]. [Italian]</TI>
<SO>Clin Ter</SO>
<YR>1986</YR>
<VL>119</VL>
<NO>4</NO>
<PG>293-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haar-1993" NAME="Haar 1993" TYPE="JOURNAL_ARTICLE">
<AU>Haar D, Solvkjaer M, Unger B, Rasmussen KJ, Christensen L, Hansen TM</AU>
<TI>A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis</TI>
<SO>Scand J Rheumatol</SO>
<YR>1993</YR>
<VL>22</VL>
<NO>3</NO>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haydu-1953" NAME="Haydu 1953" TYPE="JOURNAL_ARTICLE">
<AU>Haydu GG</AU>
<TI>Rheumatoid arthritis therapy: A rationale and the use of chloroquine diphosphate</TI>
<SO>Am J Med Sci</SO>
<YR>1953</YR>
<VL>225</VL>
<PG>71-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Landewe-1994" NAME="Landewe 1994" TYPE="JOURNAL_ARTICLE">
<AU>Landewe RB, Goei The HS, van Rijthoven AW, Breedveld FC, Dijkmans BA</AU>
<TI>A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>1994</YR>
<VL>37</VL>
<NO>5</NO>
<PG>637-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1993" NAME="Martin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Martin MFR, Dixon JS, Sitton NG, Wright V</AU>
<TI>Studies of D-penicillamine and hydroxychloroquine used in combination in the treatment of rheumatoid arthritis</TI>
<SO>Journal of Drug Development</SO>
<YR>1993</YR>
<VL>5</VL>
<NO>4</NO>
<PG>(pp 207-14)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nuver_x002d_Zwart-1989" NAME="Nuver-Zwart 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nuver-Zwart IH, van Riel PL, van de Putte LB, Gribnau FW</AU>
<TI>A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine</TI>
<SO>Ann Rheum Dis</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>5</NO>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dell-1996" NAME="O'Dell 1996" NOTES="&lt;p&gt;O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J.Rheumatol. 1996;23(SUPPL. 44):(pp 72-4).&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>O'Dell JR, Haire C, Erikson N, Drymalski W, Palmer W, Maloley P, Klassen LW, Wees S, Moore GF</AU>
<TI>Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J.Rheumatol. 1996;23(SUPPL</TI>
<VL>23</VL>
<NO>SUPPL. 44</NO>
<PG>(pp 72-4)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dell-J-1996" NAME="O'Dell J 1996" TYPE="JOURNAL_ARTICLE">
<AU>O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, Garwood V, Maloley P, Klassen LW, Wees S, et al</AU>
<TI>Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medication s. N.Engl.J.Med</TI>
<YR>1996</YR>
<VL>334</VL>
<NO>20</NO>
<PG>1287-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Page-1951" NAME="Page 1951" TYPE="JOURNAL_ARTICLE">
<AU>Page F</AU>
<TI>Treatment of lupus erythematosus with mepacrine</TI>
<SO>Lancet</SO>
<YR>1951</YR>
<VL>2</VL>
<PG>755-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pavelka-1989" NAME="Pavelka 1989" NOTES="&lt;p&gt;Pavelka K, Jr., Sen KP, Peliskova Z, Vacha J, Trnavsky K. Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens. Ann Rheum Dis 1989;48(7):542-6.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Pavelka K, Jr</AU>
<TI>, Sen KP, Peliskova Z, Vacha J, Trnavsky K. Hydroxychloroquine sulphate in the treatment of rheumatoid arthritis: a double blind comparison of two dose regimens</TI>
<SO>Ann Rheum Dis</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>7</NO>
<PG>542-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Payne-1984" NAME="Payne 1984" TYPE="JOURNAL_ARTICLE">
<AU>Payne JF</AU>
<TI>A post-graduate lecture on lupus erythematosus</TI>
<SO>Clin J</SO>
<YR>1984</YR>
<VL>IV</VL>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Porter-1993" NAME="Porter 1993" TYPE="JOURNAL_ARTICLE">
<AU>Porter DR, Capell HA, Hunter J</AU>
<TI>Combination therapy in rheumatoid arthritis--no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy</TI>
<SO>J Rheumatol</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>4</NO>
<PG>645-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rao-1995" NAME="Rao 1995" TYPE="JOURNAL_ARTICLE">
<AU>Rao UR, Naidu MU, Kumar TR, Shobha U, Askar MA, Ahmed N, Sarada P, Venubabu K, Shantaram V, Menon GN, et al</AU>
<TI>Comparison of phenytoin with auranofin and chloroquine in rheumatoid arthritis--a double blind study. J.Rheumatol</TI>
<YR>1995</YR>
<VL>22</VL>
<NO>7</NO>
<PG>1235-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scherbel-1957" NAME="Scherbel 1957" TYPE="JOURNAL_ARTICLE">
<AU>Scherbel AL, Schuchter SL, Harrison JW</AU>
<TI>Comparison of two anti-malarial agents, hydroxychloroquine sulphate and chloroquine phosphate, in patients with rheumatoid arthritis. Cleve Clin Q</TI>
<YR>1957</YR>
<VL>28</VL>
<PG>94-103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Scott-1989" NAME="Scott 1989" TYPE="JOURNAL_ARTICLE">
<AU>Scott DL, Dawes PT, Tunn E, Fowler PD, Shadforth MF, Fisher J, Clarke S, Collins M, Jones P, Popert AJ, et al</AU>
<TI>Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo- controlled study</TI>
<SO>Br J Rheu matol</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>2</NO>
<PG>128-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trnavsky-1993" NAME="Trnavsky 1993" TYPE="JOURNAL_ARTICLE">
<AU>Trnavsky K, Gatterova J, Linduskova M, Peliskova Z</AU>
<TI>Combination therapy with hydroxychloroquine and methotrexate in rheumatoid arthritis</TI>
<SO>Z Rheumatol</SO>
<YR>1993</YR>
<VL>52</VL>
<NO>5</NO>
<PG>292-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-den-Borne-96" NAME="Van den Borne 96" TYPE="JOURNAL_ARTICLE">
<AU>van den Borne BE, Landewe RB, The HS, Breedveld FC, Dijkmans BA</AU>
<TI>Low dose cyclosporine in early rheumatoid arthritis: effective and safe after two years of therapy when compared with chloroquine. Scand.J.Rheumatol</TI>
<YR>1996</YR>
<VL>25</VL>
<NO>5</NO>
<PG>307-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-der-Heijde-89" NAME="Van der Heijde 89" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, vad de Putte LB</AU>
<TI>Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<NO>8646</NO>
<PG>1036-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Riel-1995" NAME="Van Riel 1995" NOTES="&lt;p&gt;Van Riel PLCM, van Gestel AM, Van de Putte LBA. Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br.J.Rheumatol. 1995;34(SUPPL. 2):(pp 40-2).&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Van Riel PLCM, van Gestel AM, Van de Putte LBA</AU>
<TI>Long-term usage and side-effect profile of sulphasalazine in rheumatoid arthritis. Br.J.Rheumatol. 1995;34(SUPPL</TI>
<VL>34</VL>
<NO>SUPPL. 2</NO>
<PG>(pp 40-2)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Riel-P-1995" NAME="Van Riel P 1995" TYPE="JOURNAL_ARTICLE">
<AU>van Riel PL, van der Heijde DM, Nuver-Zwart IH, van de Putte LB</AU>
<TI>Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J.Rheumatol</TI>
<YR>1995</YR>
<VL>22</VL>
<NO>9</NO>
<PG>1797-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Van-Schaardenburg-95" NAME="Van Schaardenburg 95" TYPE="JOURNAL_ARTICLE">
<AU>van Schaardenburg D, Valkema R, Dijkmans BA, Papapoulos S, Zwinderman, AH, Han KH, Pauwels EK, Breedveld FC</AU>
<TI>Prednisone treatment of elderly-onset rheumatoid arthritis. Disease activity and bone mass in comparison with chloroquine treatment. Arthritis R heum</TI>
<YR>1995</YR>
<VL>38</VL>
<NO>3</NO>
<PG>334-42</PG>
<IDENTIFIERS/>
</REFERENCE>
</PENDING_REFERENCES>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Blackburn-1995">
<CHAR_METHODS>
<P>Randomized allocation<BR/>Double blind allocation and assessment<BR/>Duration - 24 wks<BR/>Sample size at entry<BR/> Hydroxychloroquine - 124<BR/> Placebo - 118</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA<BR/>Females - 75.5%<BR/>Mean age - 51.6 yrs<BR/>Duration of disease - 4.4 yrs<BR/>Prevalence of RF not reported<BR/>No previous DMARDS<BR/>Concomitant use of steroids - 24%<BR/>No concomitant use of other DMARDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hydroxychloroquine - 400 mg/day and piroxicam - 20 mg/day<BR/>Piroxicam - 20 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints<BR/>Swollen joints<BR/>Pain (0-100 VAS)<BR/>Physician global (1-5)<BR/>Patient global (1-5)<BR/>ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 5<BR/>Three arm parallel study comparing tenidap, piroxicam, and piroxicam + hydroxychloroquine - only the last 2 arms used in this review<BR/>Intent to treat analysis - last information carried forward<BR/>Withdrawals from adverse reactions could only be analyzed for specific systems</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Clark-1993">
<CHAR_METHODS>
<P>Randomized allocation<BR/>Double blind allocation and assessment<BR/>Duration 24 wks<BR/>Sample size at entry<BR/> Hydroxychloroquine - 65<BR/> Placebo - 61</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA<BR/>Mean age - 37.5 yrs<BR/>Females- 92%<BR/>Duration of disease - 29 months<BR/>Prevalence of RF - 48.5%<BR/>No previous treatment with DMARDS<BR/>No concomitant use of steroids or other DMARDs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hydroxychloroquine - 400 mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender and swollen joints (sum)<BR/>Pain (0-10 VAS)<BR/>Physician global assessment<BR/>Patient global assessment</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Intent to treat in 121 patients (5 lost to follow up before first return visit)<BR/>Joint score pooled with both tender joints and swollen joints.<BR/>Standard deviations not reported - estimated from the other trials<BR/>Withdrawals due to lack of effect were not reported<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Davis-1991">
<CHAR_METHODS>
<P>Randomized allocation<BR/>Double blind allocation and assessment<BR/>Duration 12 months<BR/>Sample size at entry<BR/> Hydroxychloroquine - 51<BR/> Placebo - 53</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with mild active RA<BR/>Median age - 46 yrs<BR/>Females - 64%<BR/>Median duration of disease: placebo - 12; treatment - 17<BR/>Prevalence of RF - 59%<BR/>No previous use of DMARDS<BR/>No concomitant use of steriods or other DMARDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hydroxychloroquine - 400mg/day<BR/>Treatment duration - 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints<BR/>Swollen joints<BR/>ESR</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 4<BR/>Data pooled for efficacy analysis at 6 months, and withdrawals at 12 months<BR/>All the outcomes reported as medians and interquartile ranges<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-HERA-1995">
<CHAR_METHODS>
<P>Randomized allocation<BR/>Double blind allocation and assessment<BR/>Duration - 36 wks<BR/>Sample size at entry<BR/> Hydroxychloroquine - 60<BR/> Placebo - 60</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients with active RA<BR/>Age - 53 yrs<BR/>Females - 75.5%<BR/>Duration of disease - &lt; 2 yrs<BR/>Prevalence of RF - 47%<BR/>No concomitant use of steriods or other DMARDS<BR/>No previous use of DMARDS</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Hydroxychloroquine - 400mg/day<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joints<BR/>Swollen joints<BR/>Pain (1-10 VAS)<BR/>Physician global<BR/>Patient global<BR/>Functional status (HAQ)<BR/>ESR<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality score: 5<BR/>One withdrawal due to protocol violation<BR/>Intent to treat analysis - last information carried forward<BR/>Only 1 withdrawal in the hydroxychloroquine group due to adverse reactions (central nervous system)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-1958">
<CHAR_REASON_FOR_EXCLUSION>
<P>Duration of trial 10 weeks</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Freedman-1960">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data reported not suitable for pooling<BR/>Short duration of trial (less than 16 weeks)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hamilton-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cross-over study - 12 weeks duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kersley-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Complex sequential design - the data could not be adequately extracted to include in the overall analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mainland-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data reported not suitable for pooling</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Popert-1961">
<CHAR_REASON_FOR_EXCLUSION>
<P>Data reported inadequate for the analysis <BR/>Duration 24 months with no reports at 6 months or 1 year comparable to the other trials</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rinehart-1957">
<CHAR_REASON_FOR_EXCLUSION>
<P>2 month cross-over trial.<BR/>Incomplete data for meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scull-1962">
<CHAR_REASON_FOR_EXCLUSION>
<P>Incomplete data for analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Blackburn-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Clark-1993">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Davis-1991">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HERA-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-09-22 00:36:42 -0400" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Antimalarials vs. placebo - Efficacy</NAME>
<CONT_OUTCOME CHI2="1.6065424695624662" CI_END="-1.3630611068606135" CI_START="-3.77950172432202" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.571281415591317" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.6579073234949504" P_Q="1.0" P_Z="3.031204146312074E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="281" UNITS="" WEIGHT="100.0" Z="4.171109302053137">
<NAME>Tender joints</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.8054154914896818" CI_START="-7.20541549148968" EFFECT_SIZE="-3.1999999999999993" ESTIMABLE="YES" MEAN_1="16.78" MEAN_2="19.98" ORDER="17133" SD_1="16.15" SD_2="15.64" SE="2.0436168843325118" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="9.099072312504502"/>
<CONT_DATA CI_END="-0.9810153277151858" CI_START="-6.318984672284815" EFFECT_SIZE="-3.6500000000000004" ESTIMABLE="YES" MEAN_1="7.35" MEAN_2="11.0" ORDER="17134" SD_1="6.84" SD_2="8.03" SE="1.3617518961253496" STUDY_ID="STD-Clark-1993" TOTAL_1="63" TOTAL_2="58" WEIGHT="20.49274346649622"/>
<CONT_DATA CI_END="-0.49219715266664155" CI_START="-3.5078028473333585" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.0" ORDER="17135" SD_1="3.75" SD_2="3.5" SE="0.769301303098789" STUDY_ID="STD-Davis-1991" TOTAL_1="44" TOTAL_2="45" WEIGHT="64.21007018879551"/>
<CONT_DATA CI_END="0.8530677072053106" CI_START="-8.85306770720531" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="19.0" ORDER="17136" SD_1="13.0" SD_2="14.0" SE="2.4761004515826257" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="6.198114032203766"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6454737665232037" CI_END="-2.5662189555751844" CI_START="-4.859319029292348" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.7127689924337663" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.885947760290311" P_Q="1.0" P_Z="2.198773339729211E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="281" UNITS="" WEIGHT="100.0" Z="6.346773602681236">
<NAME>Number of swollen joints</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-2.1783094060107357" CI_START="-6.641690593989268" EFFECT_SIZE="-4.410000000000002" ESTIMABLE="YES" MEAN_1="13.76" MEAN_2="18.17" ORDER="17137" SD_1="8.91" SD_2="8.8" SE="1.1386385727454977" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="26.39478077529117"/>
<CONT_DATA CI_END="-1.7046901697347685" CI_START="-5.595309830265232" EFFECT_SIZE="-3.6500000000000004" ESTIMABLE="YES" MEAN_1="7.35" MEAN_2="11.0" ORDER="17138" SD_1="5.15" SD_2="5.72" SE="0.9925232532891357" STUDY_ID="STD-Clark-1993" TOTAL_1="63" TOTAL_2="58" WEIGHT="34.73829208041658"/>
<CONT_DATA CI_END="-1.107234706995217" CI_START="-5.892765293004783" EFFECT_SIZE="-3.5" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="13.5" ORDER="17139" SD_1="6.0" SD_2="5.5" SE="1.2208210517533027" STUDY_ID="STD-Davis-1991" TOTAL_1="44" TOTAL_2="45" WEIGHT="22.960736995890535"/>
<CONT_DATA CI_END="-0.12518483136965175" CI_START="-5.874815168630349" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="12.0" ORDER="17140" SD_1="8.0" SD_2="8.0" SE="1.4667693852063217" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="15.906190148401713"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="16.910741582823697" CI_END="-0.18275868384726907" CI_START="-0.7187668544599852" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.4507627691536272" ESTIMABLE="YES" I2="88.17319754899803" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="2.127566106008283E-4" P_Q="1.0" P_Z="9.789328969668893E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="247" TOTAL_2="237" UNITS="" WEIGHT="99.99999999999999" Z="3.2965124098863585">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.5677808279722205" CI_START="-5.25221917202778" EFFECT_SIZE="-2.91" ESTIMABLE="YES" MEAN_1="11.06" MEAN_2="13.97" ORDER="17141" SD_1="9.47" SD_2="9.12" SE="1.195031740635494" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="1.3092656244925684"/>
<CONT_DATA CI_END="-6.322211772664998" CI_START="-20.877788227335003" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="20.5" MEAN_2="34.1" ORDER="17142" SD_1="17.84" SD_2="22.51" SE="3.713225490234141" STUDY_ID="STD-Clark-1993" TOTAL_1="63" TOTAL_2="58" WEIGHT="0.13560759074896822"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17143" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Davis-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.13003851791914256" CI_START="-0.6699614820808573" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="1.2" ORDER="17144" SD_1="0.7" SD_2="0.8" SE="0.13773798100897724" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="98.55512678475846"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5922608456309352" CI_END="-0.20682399149133737" CI_START="-0.568461397356964" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.38764269442415067" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.441546344830989" P_Q="1.0" P_Z="2.647900713353109E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="180" UNITS="" WEIGHT="100.0" Z="4.2018093682693145">
<NAME>Physician global assessment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.16595993401713105" CI_START="-0.5540400659828687" EFFECT_SIZE="-0.3599999999999999" ESTIMABLE="YES" MEAN_1="2.42" MEAN_2="2.78" ORDER="17145" SD_1="0.78" SD_2="0.76" SE="0.09900185284700744" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="86.83681217897579"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17146" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Clark-1993" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17147" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Davis-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.07161746988367684" CI_START="-1.0683825301163228" EFFECT_SIZE="-0.5699999999999998" ESTIMABLE="YES" MEAN_1="-1.67" MEAN_2="-1.1" ORDER="17148" SD_1="1.3" SD_2="1.47" SE="0.2542814735615046" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="13.163187821024204"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.037705474440887" CI_END="-0.14707516266417398" CI_START="-0.5312252225763303" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.33915019262025214" ESTIMABLE="YES" I2="50.92519441385985" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.15344136880440284" P_Q="1.0" P_Z="5.386884013832284E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="180" UNITS="" WEIGHT="100.0" Z="3.460742205988558">
<NAME>Patient global assessment</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="-0.07146076788780259" CI_START="-0.4885392321121979" EFFECT_SIZE="-0.28000000000000025" ESTIMABLE="YES" MEAN_1="2.61" MEAN_2="2.89" ORDER="17149" SD_1="0.78" SD_2="0.87" SE="0.10639952252037715" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="84.83328394352515"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17150" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Clark-1993" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17151" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Davis-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.17679765653456897" CI_START="-1.1632023434654308" EFFECT_SIZE="-0.6699999999999999" ESTIMABLE="YES" MEAN_1="-2.07" MEAN_2="-1.4" ORDER="17152" SD_1="1.21" SD_2="1.52" SE="0.251638472622838" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="15.166716056474858"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.3884029405807744E-33" CI_END="0.17363656538351305" CI_START="-0.2936365653835131" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.060000000000000046" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.0" P_Q="1.0" P_Z="0.6147276261428231" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="63" UNITS="" WEIGHT="100.0" Z="0.5033366197596988">
<NAME>Functional status</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17153" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Blackburn-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17154" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Clark-1993" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17155" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Davis-1991" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.17363656538351305" CI_START="-0.2936365653835131" EFFECT_SIZE="-0.06000000000000005" ESTIMABLE="YES" MEAN_1="0.69" MEAN_2="0.75" ORDER="17156" SD_1="0.66" SD_2="0.64" SE="0.11920451968832514" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.1776925918450867" CI_END="-4.242263061311816" CI_START="-8.510245799727912" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-6.3762544305198645" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.7583594250527912" P_Q="1.0" P_Z="4.733791945917205E-9" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="290" TOTAL_2="281" UNITS="" WEIGHT="100.0" Z="5.856269720866197">
<NAME>ESR</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="1.9091779872158723" CI_START="-11.369177987215881" EFFECT_SIZE="-4.730000000000004" ESTIMABLE="YES" MEAN_1="31.11" MEAN_2="35.84" ORDER="17157" SD_1="24.83" SD_2="27.7" SE="3.387397951995478" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" WEIGHT="10.331340945013329"/>
<CONT_DATA CI_END="4.622738390202301" CI_START="-10.822738390202304" EFFECT_SIZE="-3.1000000000000014" ESTIMABLE="YES" MEAN_1="30.1" MEAN_2="33.2" ORDER="17158" SD_1="21.37" SD_2="21.91" SE="3.9402450509898532" STUDY_ID="STD-Clark-1993" TOTAL_1="63" TOTAL_2="58" WEIGHT="7.6355912347312875"/>
<CONT_DATA CI_END="-4.500458853489077" CI_START="-9.499541146510923" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="17.0" ORDER="17159" SD_1="5.5" SD_2="6.5" SE="1.275299529086751" STUDY_ID="STD-Davis-1991" TOTAL_1="44" TOTAL_2="45" WEIGHT="72.88946063287406"/>
<CONT_DATA CI_END="1.0572236109190598" CI_START="-13.05722361091906" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="27.0" MEAN_2="33.0" ORDER="17160" SD_1="17.0" SD_2="22.0" SE="3.600690454817302" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" WEIGHT="9.143607187381319"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.5932685099674815E-33" CI_END="2.005341408984244" CI_START="-1.205341408984244" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.39999999999999997" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.0" P_Q="1.0" P_Z="0.6252944019632536" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="46" TOTAL_2="49" UNITS="" WEIGHT="100.00000000000001" Z="0.48836066236656595">
<NAME>Radiological scores</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17161" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Blackburn-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
<CONT_DATA CI_END="2.005341408984244" CI_START="-1.205341408984244" EFFECT_SIZE="0.3999999999999999" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="2.9" ORDER="17162" SD_1="4.0" SD_2="3.8" SE="0.8190667898221458" STUDY_ID="STD-Davis-1991" TOTAL_1="44" TOTAL_2="47" WEIGHT="100.00000000000001"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="0.0" MEAN_2="0.0" ORDER="17163" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-HERA-1995" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="3" TOTAL_2="3" WEIGHT="0.0" Z="0.0">
<NAME>Patients with erosions</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17164" O_E="0.0" SE="0.0" STUDY_ID="STD-Blackburn-1995" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17165" O_E="0.0" SE="0.0" STUDY_ID="STD-Davis-1991" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17166" O_E="0.0" SE="0.0" STUDY_ID="STD-HERA-1995" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-09-22 00:36:42 -0400" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Antimalarials vs. placebo - Withdrawals and dropouts</NAME>
<DICH_OUTCOME CHI2="3.144967466121852" CI_END="0.8582771480015567" CI_START="0.40749886159730053" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5913940824404758" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="90" I2="4.6095060659122025" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.06637245059862752" LOG_CI_START="-0.38987360018216694" LOG_EFFECT_SIZE="-0.2281230253903972" METHOD="PETO" NO="1" P_CHI2="0.36980989266188047" P_Q="1.0" P_Z="0.005706041659819542" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="299" TOTAL_2="292" WEIGHT="100.0" Z="2.7642122099725928">
<NAME>Withdrawals and dropouts - Total</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.3150290034943093" CI_START="0.45283236889512185" EFFECT_SIZE="0.7716784944639312" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" LOG_CI_END="0.11893533147112105" LOG_CI_START="-0.3440625369211583" LOG_EFFECT_SIZE="-0.11256360272501861" ORDER="17167" O_E="-3.5041322314049594" SE="0.27196723977003634" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" VAR="13.51969246823208" WEIGHT="48.81953893206381"/>
<DICH_DATA CI_END="1.6431652902157299" CI_START="0.28690610851385534" EFFECT_SIZE="0.6866106313339714" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.21568125242957356" LOG_CI_START="-0.5422602050979596" LOG_EFFECT_SIZE="-0.16328947633419305" ORDER="17168" O_E="-1.8968253968253972" SE="0.4452185640223972" STUDY_ID="STD-Clark-1993" TOTAL_1="65" TOTAL_2="61" VAR="5.04491055681532" WEIGHT="18.217145687000354"/>
<DICH_DATA CI_END="0.8726757112609266" CI_START="0.15840857410681625" EFFECT_SIZE="0.37180548016199955" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="20" LOG_CI_END="-0.0591471113624243" LOG_CI_START="-0.8002213152559913" LOG_EFFECT_SIZE="-0.42968421330920786" ORDER="17169" O_E="-5.221153846153847" SE="0.4353106557435534" STUDY_ID="STD-Davis-1991" TOTAL_1="51" TOTAL_2="53" VAR="5.2771738740162" WEIGHT="19.05584731303382"/>
<DICH_DATA CI_END="0.9799687200456648" CI_START="0.13296812667187397" EFFECT_SIZE="0.36097729139310986" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="13" LOG_CI_END="-0.008787786479308366" LOG_CI_START="-0.8762524497806629" LOG_EFFECT_SIZE="-0.44252011812998565" ORDER="17170" O_E="-3.92436974789916" SE="0.5095530372425521" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" VAR="3.8514229221100207" WEIGHT="13.90746806790202"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1377309673913114" CI_END="0.9050497190988921" CI_START="0.32895300736941374" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5456361671630865" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="45" I2="6.442857847514157" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.043327562079677834" LOG_CI_START="-0.4828661388215271" LOG_EFFECT_SIZE="-0.2630968504506025" METHOD="PETO" NO="2" P_CHI2="0.3433980908288127" P_Q="1.0" P_Z="0.018957211828359282" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="232" WEIGHT="100.0" Z="2.3463713021574457">
<NAME>Withdrawals due to lack of efficacy</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="1.7195874282740369" CI_START="0.38943858843211654" EFFECT_SIZE="0.8183359339248487" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="17" LOG_CI_END="0.23542426137450415" LOG_CI_START="-0.40956101760074193" LOG_EFFECT_SIZE="-0.08706837811311889" ORDER="17171" O_E="-1.3966942148760317" SE="0.37886754559868213" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" VAR="6.966669226786257" WEIGHT="46.440233014959645"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="17172" O_E="0.0" SE="0.0" STUDY_ID="STD-Clark-1993" TOTAL_1="1" TOTAL_2="1" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9214811960706376" CI_START="0.15740685658272713" EFFECT_SIZE="0.3808509662237588" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.035513522654438204" LOG_CI_START="-0.80297635386268" LOG_EFFECT_SIZE="-0.4192449382585592" ORDER="17173" O_E="-4.75" SE="0.45081146605400524" STUDY_ID="STD-Davis-1991" TOTAL_1="51" TOTAL_2="53" VAR="4.920509708737863" WEIGHT="32.800411500456676"/>
<DICH_DATA CI_END="1.180811381310796" CI_START="0.12808121778315465" EFFECT_SIZE="0.3888955639892229" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.0721805304686806" LOG_CI_START="-0.8925145518414896" LOG_EFFECT_SIZE="-0.4101670106864045" ORDER="17174" O_E="-2.9411764705882355" SE="0.5666666666666667" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" VAR="3.114186851211073" WEIGHT="20.759355484583686"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4890160368120708" CI_END="1.753661288381661" CI_START="0.3961888542623665" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8335352761630402" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.24394571514644828" LOG_CI_START="-0.40209774636546314" LOG_EFFECT_SIZE="-0.07907601560950743" METHOD="PETO" NO="3" P_CHI2="0.684807761194328" P_Q="1.0" P_Z="0.631368918366509" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="297" TOTAL_2="289" WEIGHT="100.0" Z="0.4798009789398795">
<NAME>Withdrawals due to adverse reactions</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="2.456767846584535" CI_START="0.44195445442061115" EFFECT_SIZE="1.0420074343666499" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3903641195607496" LOG_CI_START="-0.35462248452645506" LOG_EFFECT_SIZE="0.017870817517147333" ORDER="17175" O_E="0.21487603305785186" SE="0.43760881898398946" STUDY_ID="STD-Blackburn-1995" TOTAL_1="124" TOTAL_2="118" VAR="5.221891799899163" WEIGHT="75.20150699166814"/>
<DICH_DATA CI_END="6.278129394729894" CI_START="0.002455350244490709" EFFECT_SIZE="0.12415718482751754" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.7978302624373067" LOG_CI_START="-2.6098865489991505" LOG_EFFECT_SIZE="-0.906028143280922" ORDER="17176" O_E="-0.5206611570247934" SE="2.0017097235080428" STUDY_ID="STD-Clark-1993" TOTAL_1="63" TOTAL_2="58" VAR="0.24957311659039685" WEIGHT="3.594152309430762"/>
<DICH_DATA CI_END="5.181062455250563" CI_START="0.053569583987483044" EFFECT_SIZE="0.5268276381711007" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7144188275326726" LOG_CI_START="-1.2710817262730627" LOG_EFFECT_SIZE="-0.2783314493701951" ORDER="17177" O_E="-0.47115384615384626" SE="1.1662928536917405" STUDY_ID="STD-Davis-1991" TOTAL_1="51" TOTAL_2="53" VAR="0.7351649121043258" WEIGHT="10.587256763671384"/>
<DICH_DATA CI_END="5.061018140957342" CI_START="0.05266575215557015" EFFECT_SIZE="0.5162773741570549" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7042378940176495" LOG_CI_START="-1.2784717089786157" LOG_EFFECT_SIZE="-0.2871169074804832" ORDER="17178" O_E="-0.4873949579831933" SE="1.1646534353708284" STUDY_ID="STD-HERA-1995" TOTAL_1="59" TOTAL_2="60" VAR="0.7372360708989479" WEIGHT="10.617083935229715"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>